This article is more than 5 years old. Information may no longer be current.
CMO of Fresenius Medical Care Renal Therapies Group to retire
Click Here to Manage Email Alerts
The chief medical officer for Fresenius Medical Care Renal Therapies Group, Dr. Jose A. Diaz-Buxo, will retire on May 31, the dialysis provider announced. Dr. Robert Kossmann will replace Diaz-Buxo as CMO and senior vice president.
Diaz-Buxo joined Fresenius Medical Care North America in 1996 as president of the company’s peritoneal dialysis services and was made CMO of the Renal Therapies Group in 2004. He played a critical role in leading the development of devices and drugs designed to improve the quality of life and longevity of patients on dialysis. Dr. Diaz-Buxo has published more than 300 peer-reviewed publications on dialysis.
Dr. Kossmann is a nephrologist in Santa Fe, NM, a member of the volunteer clinical faculty at the University of New Mexico’s Department of Medicine, and president of the Renal Physicians Association (RPA). Kossmann has also served as nephrology advisor to the American Medical Association’s Relative Value Scale Update Committee, was a founding member of the Nephrology Coverage Advocacy Program, and founded the New Mexico Renal Disease Collaborative Group.
Kossmann must step down as president of the RPA prior to assuming the FMC position, according to the association's conflict of interest policy.
"When I accepted the job with Fresenius I knew that I would need to give up two things I value and love," Kossmann wrote in a memo to RPA members. "One is taking care of patients and building long term relationships with them and their families. The second is that I will not be able to complete my full term as RPA president. This association has strengthened my management and leadership skills, has enabled me to meet many of you, and has allowed me the opportunity to work on solving some of the many problems facing practicing nephrologists in their efforts to serve patients with kidney diseases. Professionally, my new position will allow me to make a difference in the lives of many more patients at a national level than was possible in my Santa Fe practice."
Related articles
Fresenius Medical Care said it expects revenue to nearly double by 2020
Fresenius Medical Care North America introduces Frenova Renal Research
Kent Thiry to step down as CEO of DaVita's kidney care division